Stock 2096 SIMCERE PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:08 2024-06-27 EDT 		5-day change 1st Jan Change
5.77 HKD -0.69% Intraday chart for Simcere Pharmaceutical Group Limited -0.17% -14.26%
06-25 Simcere-Mabpharm Cancer Drug Gets Marketing Approval in China MT
06-25 Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
PR
Simcere-Mabpharm Cancer Drug Gets Marketing Approval in China
MT
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China
CI
Jiaxing Andicon Biotech Co., Ltd. announced that it has received CNY 200 million in funding from a group of investors
CI
Simcere Pharmaceutical Group Limited commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024.
CI
Simcere Pharma Shareholders Approve Up to 500 Million Yuan Share Buyback
MT
Simcere Pharmaceutical Group Limited's Equity Buyback announced on June 29, 2023, has expired.
CI
Simcere Pharmaceutical’s Cancer Drug Shows Positive Results
MT
Simcere Pharma Presents Results of Phase 3 Trial for Anti-Cancer Injection at US Oncology Society Meeting
MT
Simcere Pharmaceutical Group Limited Announces Results of the Phase III Clinical Trial of ENZESHU for the Treatment Ofplatinum-Resistant Ovarian Cancer Were Presented at the ASCO Annual Meeting
CI
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China
CI
Simcere Pharmaceutical Group's Hypnotic Drugs Gets the Nod from Hong Kong Authorities
MT
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong
CI
Simcere Pharmaceutical’ Profit Down 23% in 2023
MT
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA
MT
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration
CI
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%
MT
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024
CI
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Simcere Pharmaceutical Group's Cancer Drug NDA Accepted by Chinese Regulator
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2096 Stock
  4. News Simcere Pharmaceutical Group Limited